Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9069, USA.
Curr Opin Rheumatol. 2012 Nov;24(6):685-93. doi: 10.1097/BOR.0b013e32835896ce.
Morphea, also known as localized scleroderma, is a disorder of excessive collagen deposition leading to thickening of the dermis and/or subcutaneous tissues and may cause significant morbidity. This review will describe new developments in the evaluation and management of morphea as well as its pathophysiology. The reader will be able to apply these findings to patient management.
The recent development of validated outcome measures (i.e. the localized scleroderma cutaneous assessment tool) as well as consensus treatment recommendations provide a platform for collaboration among specialties to develop both standardized assessment tools and therapeutic trials. New studies have also begun to investigate the immunological underpinnings of morphea.
The promise of evidence-based treatments for morphea in the near future will provide better care for patients with morphea and understanding its pathophysiology will lay groundwork for the development of new treatments.
硬斑病,也称局限性硬皮病,是一种胶原过度沉积导致真皮和/或皮下组织增厚的疾病,可能导致严重的发病率。本综述将描述硬斑病的评估和治疗新进展及其病理生理学。读者将能够将这些发现应用于患者管理。
最近开发的经过验证的结局评估工具(即局限性硬皮病皮肤评估工具)以及共识治疗建议为各专业之间的合作提供了一个平台,以制定标准化的评估工具和治疗试验。新的研究也开始研究硬斑病的免疫学基础。
硬斑病的循证治疗方法有望在不久的将来为硬斑病患者提供更好的护理,而对其病理生理学的理解将为新治疗方法的发展奠定基础。